These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 26811177)

  • 1. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
    Phillips RM
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
    Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
    Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
    Hunter FW; Wouters BG; Wilson WR
    Br J Cancer; 2016 May; 114(10):1071-7. PubMed ID: 27070712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy.
    Li Y; Zhao L; Li XF
    Front Oncol; 2021; 11():700407. PubMed ID: 34395270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of hypoxia-activated prodrugs in cancer therapy.
    Denny WA
    Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
    Smith PJ; McKeown SR; Patterson LH
    IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.
    Sun Z; Zhang H; Wu J; Gao F; Zhang C; Hu X; Liu Q; Wei Y; Zhuang J; Huang X
    Mol Pharm; 2020 Jun; 17(6):2072-2082. PubMed ID: 32352301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
    Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
    Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
    Denny WA
    Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
    Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
    Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
    Liang D; Miller GH; Tranmer GK
    Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoxia-targeted drug delivery.
    Sharma A; Arambula JF; Koo S; Kumar R; Singh H; Sessler JL; Kim JS
    Chem Soc Rev; 2019 Feb; 48(3):771-813. PubMed ID: 30575832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy.
    Wang W; Cheng Y; Yu P; Wang H; Zhang Y; Xu H; Ye Q; Yuan A; Hu Y; Wu J
    Nat Commun; 2019 Apr; 10(1):1580. PubMed ID: 30952842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape.
    Hamis S; Kohandel M; Dubois LJ; Yaromina A; Lambin P; Powathil GG
    PLoS Comput Biol; 2020 Aug; 16(8):e1008041. PubMed ID: 32745136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
    Hunter FW; Jaiswal JK; Hurley DG; Liyanage HD; McManaway SP; Gu Y; Richter S; Wang J; Tercel M; Print CG; Wilson WR; Pruijn FB
    Biochem Pharmacol; 2014 May; 89(2):224-35. PubMed ID: 24632291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for bioreductive drug development.
    Phillips RM
    Expert Opin Investig Drugs; 1998 Jun; 7(6):905-28. PubMed ID: 15992006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
    Patterson LH; McKeown SR
    Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers.
    Zhang H; Shi C; Han F; Li M; Ma H; Sui R; Long S; Sun W; Du J; Fan J; Piao H; Peng X
    Biomaterials; 2022 Oct; 289():121770. PubMed ID: 36075142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
    Yilmaz D; Tuzer M; Unlu MB
    Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.